Etodolac transdermal cubosomes for the treatment of rheumatoid arthritis: Ex vivo permeation and in vivo pharmacokinetic studies

Drug Delivery

Volumn 24, Issue 1, 2017, Pages 846-856

  Salah, Salwa ^a   Mahmoud, Azza A ^b,c   Kamel, Amany O ^d  

^a CAIRO UNIVERSITY   (Egypt)

^b NATIONAL RESEARCH CENTRE   (Egypt)

^c Future University in Egypt   (Egypt)

^d African Union Organization St Abbassia   (Egypt)

Author keywords

Cubosomes; Etodolac; Ex vivo; Human bioavailability; Transdermal

Indexed keywords

CUBOSOME; ETODOLAC; GLYCEROL OLEATE; NANOCARRIER; NANOPARTICLE; POLOXAMER; UNCLASSIFIED DRUG;

ADULT; ANALGESIA; ANIMAL TISSUE; ARTHRALGIA; ARTICLE; AUC (0-48 H); CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG PENETRATION; DRUG TARGETING; ELIMINATION HALF-LIFE; ELIMINATION RATE CONSTANT; EMULSION; EX VIVO STUDY; FLOW KINETICS; HOMOGENIZATION; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; JOINT STIFFNESS; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NANOENCAPSULATION; NEWBORN; NONHUMAN; NORMAL HUMAN; PARTICLE SIZE; PH; PHYSICAL PHENOMENA; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; SKIN; SUSTAINED DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; VISCOSITY; X RAY DIFFRACTION; ZETA POTENTIAL; ANIMAL; CUTANEOUS DRUG ADMINISTRATION; DRUG RELEASE;

ADMINISTRATION, CUTANEOUS; ANIMALS; ARTHRITIS, RHEUMATOID; DRUG LIBERATION; ETODOLAC; HUMANS; PARTICLE SIZE;

EID: 85032946161     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.1080/10717544.2017.1326539     Document Type: Article

References (59)

1. Association WM. (2001). World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Organ 79:373.
2. Baber N. (1994). International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH). Br J Clin Pharmacol 37:401-4.
3. Barry, B.W. (ed.) (1983) Dermatologic formulations: percutaneous absorption. New York: Marcel Dekker.
4. Bondi ML, Fontana G, Carlisi B, Giammona G. (2003). Preparation and characterization of solid lipid nanoparticles containing cloricromene. Drug Deliv 10:245-50.
5. Caboi F, Nylander T, Razumas V, et al. (1997). Structural effects, mobility, and redox behavior of vitamin K1 hosted in the monoolein/ water liquid crystalline phases. Langmuir 13:5476-83.
6. Caffrey M. (1987). Kinetics and mechanism of transitions involving the lamellar, cubic, inverted hexagonal, and fluid isotropic phases of hydrated monoacylglycerides monitored by time-resolved X-ray diffraction. Biochemistry 26:6349-63.
7. Chantasart D, Li SK, He N, et al. (2004). Mechanistic studies of branched-chain alkanols as skin permeation enhancers. J Pharm Sci 93:762-79.
8. Colebatch AN, Marks JL, Edwards CJ. (2011). Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database Syst Rev 2011;(11):CD008872.
9. El-Leithy ES, Ibrahim HK, Sorour RM. (2015). In vitro and in vivo evaluation of indomethacin nanoemulsion as a transdermal delivery system. Drug Deliv 22:1010-7.
10. Elias PM, Williams ML, Maloney ME, et al. (1984). Stratum corneum lipids in disorders of cornification. Steroid sulfatase and cholesterol sulfate in normal desquamation and the pathogenesis of recessive X-linked ichthyosis. J Clin Invest 74:1414-21.
11. Elshafeey AH, Kamel AO, Fathallah MM. (2009). Utility of nanosized microemulsion for transdermal delivery of tolterodine tartrate: ex-vivo permeation and in-vivo pharmacokinetic studies. Pharm Res 26: 2446-53.
12. Esposito E, Cortesi R, Drechsler M, et al. (2005). Cubosome dispersions as delivery systems for percutaneous administration of indomethacin. Pharm Res 22:2163-73.
13. Feczkó T, Tóth J, Dósa G, Gyenis J. (2011). Influence of process conditions on the mean size of PLGA nanoparticles. Chem Eng Process Process Intens 50:846-53.
14. Ganem-Quintanar A, Quintanar-Guerrero D, Buri P. (2000). Monoolein: a review of the pharmaceutical applications. Drug Dev Ind Pharm 26: 809-20.
15. Gustafsson J, Ljusberg-Wahren H, Almgren M, Larsson K. (1996). Cubic lipid-water phase dispersed into submicron particles. Langmuir 12: 4611-3.
16. Gustafsson J, Ljusberg-Wahren H, Almgren M, Larsson K. (1997). Submicron particles of reversed lipid phases in water stabilized by a nonionic amphiphilic polymer. Langmuir 13:6964-71.
17. Hadgraft J. (2001). Skin, the final frontier. Int J Pharm 224:1-18.
18. Hans ML, Lowman AM. (2002). Biodegradable nanoparticles for drug delivery and targeting. Curr Opinion Solid State Mat Sci 6:319-27.
19. Hundekar YR, Saboji JK, Patil SM, Nanjwade BK. (2014). Preparation and evaluation of diclofenac sodium cubosomes for percutaneous administration. wjpps 3:523-39.
20. Hyde S, Andersson S. (1984). A cubic structure consisting of a lipid bilayer forming an infinite periodic minimum surface of the gyroid type in the glycerolmonooleat-water system. Zeitschrift Für Kristallographie-Crystalline Materials 168:213-20.
21. Jain SK, Chourasia MK, Masuriha R, et al. (2005). Solid lipid nanoparticles bearing flurbiprofen for transdermal delivery. Drug Deliv 12:207-15.
22. James E, Reynolds F. 1996. Martindale: The extra pharmacopoeia. London: Royal Pharmaceutical Society.
23. Joge P, Kanchan DK, Sharma P, Gondaliya N. (2013). Effect of nanofiller on electrical properties of PVA-PEO blend polymer electrolyte. IJPAP 51:350-3.
24. Jones RA. (1999). Etodolac: an overview of a selective COX-2 inhibitor. Inflammopharmacology 7:269-75.
25. Kim YH, Ghanem AH, Higuchi WI. (1992). Model studies of epidermal permeability. Semin Dermatol 11:145-56.
26. Kohli AK, Alpar HO. (2004). Potential use of nanoparticles for transcutaneous vaccine delivery: effect of particle size and charge. Int J Pharm 275:13-7.
27. Korsmeyer RW, Gurny R, Doelker E, et al. (1983). Mechanisms of potassium chloride release from compressed, hydrophilic, polymeric matrices: effect of entrapped air. J Pharm Sci 72:1189-91.
28. Kwon TK, Hong SK, Kim J-C. (2012). In vitro skin permeation of cubosomes containing triclosan. J Ind Eng Chem 18:563-7.
29. Kwon TK, Kim J-C. (2010). Preparation and in vitro skin permeation of cubosomes containing hinokitiol. J Disper Sci Tech 31:1004-9.
30. Kwon TK, Lee HY, Dai Kim J, et al. (2010). In vitro skin permeation of cubosomes containing water soluble extracts of Korean barberry. Colloid J 72:205-10.
31. Lampe MA, Williams ML, Elias PM. (1983). Human epidermal lipids: characterization and modulations during differentiation. J Lipid Res 24:131-40.
32. Landh T, Larsson K. (1996). Particles, method of preparing said particles and uses thereof. US Patent 5:925.
33. Larsson K. (1989). Cubic lipid-water phases: structures and biomembrane aspects. J Phys Chem 93:7304-14.
34. Larsson K. (2000). Aqueous dispersions of cubic lipid-water phases. Curr Opin Colloid Interface Sci 5:64-9.
35. Li S, Ghanem A, Yoneto K, Higuchi W. (1997). Effects of 1-alkyl-2-pyrrolidones on the lipoidal pathway of human epidermal membrane: A comparison with hairless mouse skin. Pharm Res 14:S-303.
36. Luzzati V, Vargas R, Mariani P, et al. (1993). Cubic phases of lipidcontaining systems. Elements of a theory and biological connotations. J Mol Biol 229:540-51.
37. Maibach HI, Smith EW. 2005. Percutaneous penetration enhancers. Boca Raton, FL: CRC Press.
38. Mainardes RM, Evangelista RC. (2005). PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharm 290:137-44.
39. Mariani P, Luzzati V, Delacroix H. (1988). Cubic phases of lipidcontaining systems. Structure analysis and biological implications. J Mol Biol 204:165-89.
40. Meier J, Nüesch E, Schmidt R. (1974). Pharmacokinetic criteria for the evaluation of retard formulations. Eur J Clin Pharmacol 7:429-32.
41. Morsi NM, Abdelbary GA, Ahmed MA. (2014). Silver sulfadiazine based cubosome hydrogels for topical treatment of burns: development and in vitro/in vivo characterization. Eur J Pharm Biopharm 86: 178-89.
42. Muller RH, Radtke M, Wissing SA. (2002). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 54 Suppl 1: S131-55.
43. Norlen L, Al-Amoudi A. (2004). Stratum corneum keratin structure, function, and formation: the cubic rod-packing and membrane templating model. J Invest Dermatol 123:715-32.
44. Pal SL, Jana U, Manna PK, et al. (2011). Nanoparticle: An overview of preparation and characterization. J Appl Pharm Sci 1: 228-34.
45. Pan X, Han K, Peng X, et al. (2013). Nanostructured cubosomes as advanced drug delivery system. Curr Pharm Des 19:6290-7.
46. Patrick TS. 2009. Cubosomes: bicontinuous liquid crystalline nanoparticles. dekker encyclopedia of nanoscience and nanotechnology. New York: Taylor & Francis.
47. Peppas NA. (1985). Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv 60:110-1.
48. Rattanapak T, Young K, Rades T, Hook S. (2012). Comparative study of liposomes, transfersomes, ethosomes and cubosomes for transcutaneous immunisation: characterisation and in vitro skin penetration. J Pharm Pharmacol 64:1560-9.
49. Raykar PV, Fung MC, Anderson BD. (1988). The role of protein and lipid domains in the uptake of solutes by human stratum corneum. Pharm Res 5:140-50.
50. Rizwan SB, Hanley T, Boyd BJ, et al. (2009). Liquid crystalline systems of phytantriol and glyceryl monooleate containing a hydrophilic protein: characterisation, swelling and release kinetics. J Pharm Sci 98:4191-204.
51. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. (2002). Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release 82:105-14.
52. Salama AH, Mahmoud AA, Kamel R. (2016). A novel method for preparing surface-modified fluocinolone acetonide loaded PLGA nanoparticles for ocular use: in vitro and in vivo evaluations. AAPS PharmSciTech 17:1159-72.
53. Salama HA, Mahmoud AA, Kamel AO, et al. (2012a). Brain delivery of olanzapine by intranasal administration of transfersomal vesicles. J Liposome Res 22:336-45.
54. Salama HA, Mahmoud AA, Kamel AO, et al. (2012b). Phospholipid based colloidal poloxamer-nanocubic vesicles for brain targeting via the nasal route. Colloids Surf B Biointerf 100:146-54.
55. Spicer PT, Small WB, Lynch MLI, Burns JL. (2002). Dry powder precursors of ‘‘soft’’ cubic liquid crystalline nanoparticles (cubosomes). J Nanopart Res 4:297-311.
56. Subongkot T, Pamornpathomkul B, Rojanarata T, et al. (2014). Investigation of the mechanism of enhanced skin penetration by ultradeformable liposomes. Int J Nanomed 9:3539-50.
57. Xu Q, Crossley A, Czernuszka J. (2009). Preparation and characterization of negatively charged poly(lactic-co-glycolic acid) microspheres. J Pharm Sci 98:2377-89.
58. Yaghmur A, Glatter O. (2009). Characterization and potential applications of nanostructured aqueous dispersions. Adv Colloid Interface Sci 147-148:333-42.
59. Yapar EA, Y ´ nal O¨. (2012). Poly (ethylene oxide)-poly (propylene oxide)-based copolymers for transdermal drug delivery: An overview. Trop J Pharm Res 11:855-66.